Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239403 | 1.00 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL17239391 | 0.80 | NOS3 (0.30) | — | |
| SCHEMBL17239392 | 0.80 | NOS3 (0.30) | — | |
| SCHEMBL5494343 | 0.75 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL17239396 | 0.75 | — | — | |
| SCHEMBL17239397 | 0.75 | — | — | |
| SCHEMBL2517574 | 0.73 | — | — | |
| SCHEMBL8675546 | 0.72 | — | — | |
| SCHEMBL8675544 | 0.72 | — | — | |
| SCHEMBL17239404 | 0.72 | ALDH1A1 (0.40) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970533-B | (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from (R) -6,10, 14-trimethylpentadeca-5-en-2-one | 帝斯曼知识产权资产管理有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2935177-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS BV (NL) | 2019-07-24 | — | — | EP | disclosed |
| EP-2935185-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14-TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE | DSM IP ASSETS BV (NL) | 2019-02-20 | — | — | EP | disclosed |
| EP-2935233-B1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| EP-2935181-B1 | EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES | DSM IP ASSETS BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| EP-2935175-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE | DSM IP ASSETS BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-2935190-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDECA-3,5,9-TRIEN-2-ONE | DSM IP ASSETS BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-2935176-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-3,7-DIMETYLOCT-6-ENAL | DSM IP ASSETS BV (NL) | 2018-08-01 | — | — | EP | disclosed |
| US-9611200-B2 | (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14 trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one | DSM IP ASSETS B.V. (NL) | 2017-04-04 | — | — | US | disclosed |
| US-9561989-B2 | Process of asymmetric hydrogenation of ketals and acetals | DSM IP ASSETS B.V. (NL) | 2017-02-07 | — | — | US | disclosed |
| US-9452961-B2 | (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one | DSM IP ASSETS B.V. (NL) | 2016-09-27 | — | — | US | disclosed |
| US-20160185683-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | disclosed |
| US-20150329457-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329456-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE | DSM IP ASSETS B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150321971-A1 | EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES | DSM IP ASSETS B.V. (NL) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329456-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE | CYP3A5, ADRA1D, HTR5A | ALDH1A1 764/4885ALOX15 756/4885 |
| US-20150321971-A1 | EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES | ADH5, ADH1A, ADH1C | ALDH1A1 61/4885ALOX15 171/4885 |
| US-20160185683-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | KAT5, AKR1D1, AKR1C2 | ALDH1A1 110/4885ALOX15 177/4885 |
| US-20150329457-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | PDE12, CYP2D6, PDE9A | ALDH1A1 568/4885ALOX15 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.